about
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectivesAssessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?A rare case of recurrent ovarian cancer presenting as a round ligament metastasisSecondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.Serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature.The history of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG).Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).Minimization of curative surgery for treatment of early cervical cancer: a review.Establishment and Characterization of an In Vitro Model of Ovarian Cancer Stem-like Cells with an Enhanced Proliferative Capacity.Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical OncolA case of vaginal clear cell adenocarcinoma complicated with congenital anomalies of the genitourinary tract and metanephric remnant without prenatal diethylstilbestrol exposure.Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA.Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma.Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study.Versatile lotus petal flap for vulvoperineal reconstruction after gynecological ablative surgery.Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix.Clinical characteristics and outcomes of women with stage IV endometrial cancer.Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation.Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101)Familial risk factors for a second primary malignancy in endometrial or ovarian carcinomaAssessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsyCD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic markerCharacterization of IgA response among women with incident HPV 16 infectionPrevalence of ovarian endometriosis in epithelial ovarian cancerDistinct lymphatic spread of endometrial carcinoma in comparison with cervical and ovarian carcinomasFeasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trialSurgical treatment for neuroendocrine carcinoma of the uterine cervixClinical aspects and prognosis of pelvic recurrence of cervical carcinomaFeasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervixThe optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatmentBifunctional roles of survivin-ΔEx3 and survivin-2B for susceptibility to apoptosis in endometrial carcinomas
P50
Q28083801-3A6D4489-4E18-452F-9BB2-9CEF0F446F53Q35234059-0DBD52B7-32B3-4FF2-824F-796E83903C7FQ35576622-5FCD8B02-5B32-40B9-86F9-5EF8E2D4F47FQ36616507-819B35CF-55DA-4E64-B089-A5A3DD0A1ED0Q37222658-FFCBC67D-0AAC-4B47-9433-B8633499FFE3Q37923698-A28AF396-B3D3-4CB8-A22E-16D907F7E320Q37926294-CEA2009C-503E-4EFB-B0A0-E97DDA613769Q38348194-F890BA79-8103-4868-BAFD-1C8D12C098B7Q38427477-78FF59EB-2072-40F9-9739-629DC6B4F2A7Q38811667-AEE0B0C0-28A2-4981-8DFF-D743103E6873Q39669919-E5AD7652-3311-4C27-8E1A-6C2B0C6EDB4EQ42991821-11E349E8-301D-4CEA-B600-B8D3355A5050Q44625824-8B20CDAC-088C-4773-8D5B-E547EF50D1D4Q44640484-B6837FFA-E625-4FBC-96A7-D61BFE788884Q48559793-3ECB7C1B-610D-4780-BF3F-22856AE2137BQ51597329-8BD056D7-F29D-4345-9937-52D9108344F1Q53170700-D5E1E928-0C03-417E-AE70-E959563DED33Q53353041-4B5E7F46-35F7-4A99-913B-D6A500D8A1E6Q53398109-FFE73214-B589-44D3-A943-BB75C73EA704Q54530132-1F265282-8ECC-4859-8544-3B4D4B5AD4D4Q64110340-01A7C4D2-BA5E-46BD-B459-DA0E9E82765FQ70974612-1C1F20B8-D419-4634-AD44-E6744DDB96BBQ71394593-805342D8-A488-4A1F-9714-987B4C47CA16Q73395765-B6BB9631-34D5-459F-BE9E-89EFAC227A74Q73733757-1E2A1904-639B-4C1B-9381-477FA66910A9Q74256318-28CCEA75-1BE5-40DA-BAA7-DAA9505C3EA8Q77815495-31F2BA2F-EE4D-4347-9948-D06BFC9A2C16Q79776209-298B19C4-D206-4E09-802B-7116D6B464DCQ80656464-655AB852-9D77-4902-B99C-86D2CA4895C3Q80825480-817A9566-682F-40D6-981B-F96A31845A1EQ81356871-C24A1463-6B78-4EF1-B35C-4BB865BA96EFQ81545686-4D1C5F54-E516-4BDA-8513-B38E629B3F25Q83268686-0FA8535F-45D6-426E-9021-937DF8CC2A00Q84574320-8344FF21-742D-4378-B6A9-FDC936EEFCABQ84699471-D74EE488-05AE-4A00-BFF0-231FFED19370Q87388333-93517E9D-E132-43BA-9FDE-A812E1FAFBEC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Takashi Onda
@ast
Takashi Onda
@en
Takashi Onda
@es
Takashi Onda
@nl
Takashi Onda
@sl
type
label
Takashi Onda
@ast
Takashi Onda
@en
Takashi Onda
@es
Takashi Onda
@nl
Takashi Onda
@sl
prefLabel
Takashi Onda
@ast
Takashi Onda
@en
Takashi Onda
@es
Takashi Onda
@nl
Takashi Onda
@sl
P106
P1153
7004456874
P31
P496
0000-0002-9935-3783